Given the immunoinhibitory effects of TIRC7 and its interaction with CTLA-4, future studies should explore the impact of TIRC7-modulation alone or in combination with immune therapy in CCA and other malignancies. This evidence concerns the gene TCIRG1 and cholangiocarcinoma.